M J Edelman

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. Edelman M, TAN M, Fidler M, Sanborn R, Otterson G, Sequist L, et al. Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. J Clin Oncol. 2015;33:189-94 pubmed publisher
    ..The median PFS for the control arm was 97 days (95% CI, 52 to 193 days) versus 85 days (95% CI, 67 to 142 days) for the experimental arm (P = .91). Apricoxib did not improve PFS, despite biomarker-driven patient selection. ..
  2. Edelman M, Watson D, Wang X, Morrison C, Kratzke R, Jewell S, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol. 2008;26:848-55 pubmed publisher
    ..However, a prospectively defined subset analysis suggests an advantage for celecoxib and chemotherapy for patients with moderate to high COX-2 expression. ..
  3. Bhooshan N, Staats P, Fulton A, Feliciano J, Edelman M. Prostaglandin E Receptor EP4 expression, survival and pattern of recurrence in locally advanced NSCLC. Lung Cancer. 2016;101:88-91 pubmed publisher
    ..There was a significant correlation between OS and nuclear EP4 expression, indicating that this is a potential therapeutic target. Studies with AT-007, a specific inhibitor of EP4, are planned to commence this year. ..
  4. Edelman M, Hodgson L, Rosenblatt P, Christenson R, Vokes E, Wang X, et al. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol. 2012;7:649-54 pubmed publisher
    ..0255 and p = 0.0068). CYFRA and change in CYFRA were found to be reliable markers for response to chemotherapy for NSCLC; however, a precise threshold to mark response has yet to be determined. ..
  5. Edelman M, Lapidus R, Feliciano J, Styblo M, Beumer J, Liu T, et al. Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. Cancer Chemother Pharmacol. 2016;78:959-967 pubmed
    ..Combinations with other platinum agents (e.g., carboplatin) should be considered. This is the first fully reported human trial of KML-001. ..
  6. Edelman M. Gemcitabine and carboplatin regimens in advanced non-small-cell lung cancer: focus on randomized phase III trials. Clin Lung Cancer. 2003;4 Suppl 2:S40-4 pubmed
    ..Its excellent toxicity profile has also led several groups to utilize the regimen as a platform for combination with newer drugs...
  7. Edelman M. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer. Clin Lung Cancer. 2005;7 Suppl 2:S64-6 pubmed
    ..This article will review the rationale for the use of bortezomib as part of the chemotherapy/RT strategy for the treatment of NSCLC...
  8. Edelman M, Schneider C, Tsai C, Kim H, Quoix E, Luft A, et al. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status. J Clin Oncol. 2013;31:1990-6 pubmed publisher